Publications

Kim BG, Malek E, Choi SH, Ignatz-Hoover J, Driscoll JJ, (2021). Novel Therapies Emerging in Oncology to Target the TGF-b Pathway. Journal of Hematology Oncology (accepted).

Kim BG, Choi SH, Driscoll JJ, Letterio J, Malek E (2021). The TGF- receptor kinase inhibitor vactosertib downregulates PSMB5 and overcomes proteasome inhibitor resistance in multiple myeloma. (in revision).

Malek E, Martin P, Covut F, Kohl M, Ferrari N, Zebrowski R, Caimi P, Metheny L, Gallogly M, de Lima M, Driscoll JJ. (2021). Impact of maintenance therapy on the nature of relapse following autologous stem cell transplantation in multiple myeloma. (in revision).

Covut F, Driscoll JJ, O’Brien T, Gerson S, de Lima M, Malek E (2021). The Impact of Age and Previous Malignancies on Outcomes of Patients with Smoldering Myeloma and Multiple Myeloma. (in revision).

Covut F, Driscoll JJ, Cooper B, Gallogly M, de Lima M, Malek E (2021). Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients. Leukemia Jan: 35(1):250-254.

Anandan A, Kolk M, Ferrari N, Copley M, Driscoll JJ, Caimi P, Rashidi A, de Lima M, Malek E (2020). Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Nephrology, (Carlton). 2020; 25(6):450‐456. doi:10.1111/nep.13712.

Tremblay, S, Driscoll, JJ, Rike‐Shields, A, et al. (2020). A prospective, iterative, adaptive trial of carfilzomib‐based desensitization. Am J Transplant. 2020; 20: 411– 421. https://doi.org/10.1111/ajt.15613.

Woodle, ES, Tremblay, S, Brailey, P, et al. (2020). Proteasomal adaptations underlying carfilzomib‐resistance in human bone marrow plasma cells. Am J Transplant. 2020; 20: 399– 410. https://doi.org/10.1111/ajt.15634.

Lee MJ, Bhattarai D, Yoo ZS, Miller Z, Park JE, Lee S, Lee W, Driscoll JJ, Kim KB, (2019). Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib. Jour. Med. Chem. 62(9): 4444-4455.

Ye R, Kundrapu S, Gerson S, Driscoll JJ, Beck R, Ali N, Landgren O,  VanHeeckeren, W, Luo G, Kroger N, Caimi P, De Lima M, Malek E. (2019). Immune signatures associated with clonal isotype switch after autologous stem cell transplantation for multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia, 19(5) e213-20.

Sundaram S, Driscoll JJ, Fernandez M, de Lima M, Malek E. (2018). FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials. Amer. Jour. Nucl. Med. & Med. Imaging 8(6):421-427.

Woodle, ES, Tremblay S, Driscoll JJ (2017). Response to IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 377:1692-1694.

Malek E, Saygin C. Ye R, Covut F, Kim B-G, de Lima M, Driscoll JJ (2017). Predicting successful regulatory approval in multiple myeloma from phase I overall response rates. Journal Clinical Oncology–Clinical Cancer Informatics, 2: 1-14, doi: 10: 1200/CCI.17.00055.

Driscoll JJ, Brailey M. (2017). Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. Cancer Metastasis Rev. 1-14, doi: 10.1007/s10555-017-9698-5.

Dosani, T, Covut F, Beck R, Driscoll JJ, de Lima M, Malek E. (2017) Significance of the absolute lymphocyte/ monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal 7:e579 doi:10.1038/bcj.2017.60.

Woodle, ES, Tremblay S, Driscoll JJ (2017). Targeting plasma cells with proteasome inhibitors:  Principles from Primates, Jour. of the Amer. Soc. Nephrol. 28: 1951-1953.

Covut F, Pinto R, Dosani T, Friedman J, Driscoll JJ et al. (2017). Impact of lenalidomide on hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Biol Blood Marrow Transplant 23 390–391.

Malek E, Abdel Malek M, Jagannathan S, Vad N, Cottini F, Anderson KC, Driscoll JJ (2016) Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes bortezomib resistance in multiple myeloma. Leukemia doi:10.1038/leu. 2016.258.

Malek E, Kim, BG, Driscoll JJ (2016) Identification of long non-coding RNAs commonly deregulated in multiple myeloma cells resistant to proteasome inhibitors. Genes: Human Genetics and Genomics, microRNAs and Other Non-Coding RNAs in Human Diseases. 7(10): 84 PMCID: PMC5083923.

Markeb A, El-Maali N, Sayed D, Osama A, Abdel-Malek M, Zaki A, Elwanis M, Driscoll JJ (2016). Synthesis, structural characterization and preclinical efficacy of a novel paclitaxel-loaded alginate nanoparticle for breast cancer treatment, International Journal of Breast Cancer. ID 7549372 http://dx.doi.org/10.1155/2016/7549372.

Driscoll JJ, Aslam I, Malek E. (2016). High throughput chemical library screens identify a novel small molecule checkpoint inhibitor that activates anti-myeloma T Cells. Clinical Lymphoma, Myeloma & Leukemia. 16 (S82) doi.org/10.1016/ j.clml.2016.07.115.

Malek E, Aslam I, Driscoll JJ. (2016) Counteracting PD-L1/PD-L2 immune suppression in multiple myeloma through kinase inhibition. American Society of Hematology 128 (22) 3295.

Tremblay S, Shields A, Alloway R, Brailey P, Abu Jawdeh B, Latif T, Driscoll JJ. (2016). A Prospective Carfilzomib-Based Desensitization Trial: Phase 1 Results. Am J Transplant. 16.

Driscoll JJ, Aronow B, Tremblay S, Alloway R, Woodle E. (2016) RNAseq transcriptome analysis of bone marrow CD138+ plasma cell responses to carfilzomib monotherapy desensitization. Am J Transplant. 2016; 16.

Girnius S, Driscoll JJ. (2016). Proteasome inhibitors to treat AL amyloidosis, in Exploring New Findings on Amyloidosis, 1-15 doi:10.5772/63467. 

Malek E, Letterrio J, Kim BG, Driscoll JJ, deLima M, Giralt S. (2016). Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Reviews. DOI: doi.org/10.1016/j.blre.2016.04.002

Malek E, Driscoll JJ. (2016) High throughput chemical library screening identifies a novel p110- inhibitor that potentiates the anti-myeloma effect of bortezomib. Oncotarget 7(25) 38523-38538.  doi: 10.18632/oncotarget.9568.

Driscoll JJ. (2016) Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib. Cancer Translational Medicine 1(5) 153-157. doi: 10.4103/2395-3977.168577.

Malek E,  Sendilnathan A, Yellu M, Peterson A, Fernandez-Ulloa M, Driscoll JJ (2015). Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer Journal 5, e326; doi:10.1038/ bcj.2015.51.

Driscoll JJ, Ludtka, T. (2015). The Promise and Challenges of Personalized Medicines in Hematologic Malignancies. J. Hematol Thromb. 1(2) 1-3. ISSN: 2380-6842.

Abdel-Malek M, Jagannathan S, Vad N, Driscoll JJ.  (2015) Molecular Chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget 6(5) 3098-3110.  doi: 10.18632/oncotarget.3075.

Jagannathan S, Vad N, Malek E, Vallabhapurapu Su, Vallabhapurapu Si, Driscoll JJ. (2015) Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells Oncotarget 5(23) 12358-12370. doi: 10.18632/oncotarget.2590.

Malek E, Driscoll JJ. (2015) Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget 5(18) 8027-8038.

Jagannathan S, Vad N, Vallabhapurapu Su, Vallabhapurapu Si, Anderson KC, Driscoll JJ. (2015). MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the anti-myeloma benefit of bortezomib. Leukemia 29(3) 727-738 doi:10.1038/leu.279.

Abdel Malek MA, Driscoll JJ. (2015). Molecular crosstalk between autophagy and apoptosis networks in cancer. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging (Ed. Hayat) 5: 51-64.

Alsiwadi S, Malek E, Driscoll JJ. (2014). MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics. Int J Mol Sci. 15(6):10508‐10526.

Medhat MA, Abdel Malek MAY, Zaki S, Helmy S, Driscoll JJ (2014). Rare extraperitoneal involvement with fatal outcome in a case of bilateral luteinized thecoma of the ovaries with sclerosing peritonitis. Case Reports in Oncology 2014:904581. doi:10.1155/2014/904581.

Abdel Malek, MAY, Sayed, DM, Ahmad, YA, Driscoll, JJ (2014). Chronic eosinophilic leukemia transformation into acute myeloid leukemia with monocytic differentiation. Case Reports in Internal Medicine 1:4-9.

Ahmad N, Abdel Malek MA, Anaissie E., Driscoll JJ (2014). Targeting the Proteasome Pathway for the Treatment of Solid Tumors. In: Dou Q. (eds) Resistance to Proteasome Inhibitors in Cancer. Resistance to Targeted Anti-Cancer Therapeutics. Springer, Cham.

Haider, S, Ahmad, N, Anaissie, E, Driscoll, JJ (2013) Future directions in the clinical management of amyloid light chain amyloidosis. Leukemia and Lymphoma (Dec. 2013; doi: 0.3109/10428194.2013.876630).

Targeting the proteasome pathway for the treatment of solid tumors, in “Resistance to proteasome inhibitors" (Ed. Q. Ping Dou) Cancer Research Springer Science. (in press).

Kim KJ, Godarova A, Seedle K, Kim MH, Ince TA, Wells SI, Driscoll JJ, Godar S. (2013) Rb suppresses collective invasion, circulation and metastasis of breast cancer cells in a CD44-Dependent manner. Plos One (Nov. 2013; doi: 10.1371/journal. pone.0080590).

Ahmad N, Haider S, Anaissie E, Driscoll JJ (2013) MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia doi:10.1038/leu.2013.262

Subramani A, Alsidawi A, Jagannathan S, Sumita K, Sasaki AT, Aronow B, Warnick RE, Lawler S, Driscoll, JJ (2013) Brain microenvironment-induced reduction in microRNA-768-3p promotes metastatic tumor growth, drug resistance and KRAS expression. Nature-Scientific Reports 3, doi:10.1038/Srep 02392.

Potluri V, Noothi SK, Vallabhapurapu SD, Yoon S-O, Driscoll JJ, Lawrie CH, Vallabhapurapu S. (2013). Transcriptional Repression by a novel YY1-RelA complex is essential for the survival and growth in multiple myeloma. PLoS ONE 8(7): e66121. Aug. 2013; doi:10.1371/journal.pone.0066121.

Driscoll JJ, Khaled A, Jagannathan S, Subramani A. (2013) The Mammalian Target of Rapamycin as a Therapeutic Strategy in Oncology in Mammalian Target of Rapamycin (mTOR): Structure, Signaling Pathways and Biological Effects.

Driscoll JJ, Khaled A, Jagannathan S, Subramani A. (2013) Targeting the PTEN Tumor Suppressor as an Anti-Cancer Therapeutic Strategy. In PTEN: Structure, Mechanisms-of-Action, Role in Cell Signaling and Regulation.

Driscoll JJ, De Chowdhury R. (2013) Molecular Crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications, Cancer Letters 325 147-154.

Driscoll JJ, Woodle ES. (2012) Targeting the ubiquitin+proteasome system in solid tumors, Sem. in Hem. 49 277-83.

Driscoll JJ, Burris J, Annunziata CM. (2012) Targeting the Proteasome with Bortezomib in Multiple Myeloma: Update on therapeutic benefit as an upfront single agent, induction regimen for stem cell transplantation and as maintenance therapy. Amer. J. Ther. 19 133-44.

Driscoll JJ (2011). The SUMOylation pathway as a potential therapeutic target in Multiple Myeloma, Multiple Myeloma- an overview. 129-136.

Driscoll JJ, Minter A, Driscoll D (2011). The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies. Anti-Cancer Agents in Medicinal Therapy, 11(2) 242-6.

Driscoll JJ, DeChowdhury R. (2010) Therapeutically Targeting the SUMOylation, Ubiquitination and Proteasome Pathways as a Novel Anticancer Strategy. Targeted Oncology 5 281-289.

Driscoll JJ, Burris J, Annunziata CM (2010). Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy, J. Cell Sci. 1 101-8.

Driscoll JJ, DeChowdhury R, Burris J et al. (2010). The Expanding Role of Proteasome-Based Therapy in the Treatment of Hematologic Malignancies. Open J. Hematology, 1 1-20.

Driscoll JJ, Rixe O. (2010) Overall Survival Remains the Gold Standard, in Cancer: Principles & Practice of Oncology. Annual Adv. in Onc. vol I, eds: Devita VT, Lawrence TS, Rosenberg SA.

Driscoll JJ, Pelluru D, Lefkimmiatis K, et al, (2010). The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 115 (2010) 2827-34.

Gabathuler R, Reid G, Kolaitis G, Driscoll JJ, Jefferies WA (1995). Comparison of Cell Lines Deficient in Antigen Presentation Reveals a Functional Role for TAP-1 Alone in Antigen Processing. J. Ex. Med. 180 1415-1425.

Driscoll JJ, Brown M, Finley DJ, Monaco JJ (1995). MHC-Linked LMP Gene Products Specifically Alter the Peptidase Activities of the Proteasome. Nature (London) 365 262- 264.

Brown M, Driscoll JJ, Monaco JJ (1994). MHC-Linked LMP and Proteasome Complexes are Not Identical: Implications for Divergent Function among Immunospecific Forms of the Proteasome. J. Immunol. 151 1193-1204.

Arnold D, Driscoll JJ, Androlewicz M, Hughes E, Cresswell P, Spies T (1994). Proteasome Subunits Encoded in the MHC are Not Generally Required for the Processing of Peptides Bound by MHC Class I Molecules. Nature (London) 360 171-174.

Driscoll JJ, Finley DJ (1994). A Controlled Breakdown: Antigen Processing and Turnover of Viral Proteins. Cell 68 823-825.

Driscoll JJ, Frydman J, Goldberg AL (1993). An ATP-Stabilized Inhibitor of the Proteasome is a Component of the 1,500-kDa Ubiquitin-Conjugate-Degrading Complex. Proc. Natl. Acad. Sci. U.S.A. 89 4986-4990.

Brown M, Driscoll JJ, Monaco JJ (1993). Structural and Serological Similarity of the MHC-Linked LMP and the Proteasome (Multicatalytic Protease) Complexes. Nature (London) 353 355-357.

Driscoll JJ, Goldberg AL (1990). The Proteasome (Multicatalytic Protease) is a Component of the 1,500-kDa Proteolytic Complex which Degrades Ubiquitin-Conjugated Proteins. J. Biol. Chem. 265 4789-4792.

Matthews W, Driscoll JJ, Tanaka K, Ichihara A, Goldberg AL (1990). Involvement of the Proteasome in Various Degradative Processes in Mammalian Cells. Proc. Natl. Acad. Sci. U.S.A. 86 2597-2601.

Driscoll JJ, and Goldberg AL. (1990) Skeletal Muscle Proteasome can Degrade Proteins in an ATP-Dependent Process that does Not Require Ubiquitin. Proc. Natl. Acad. Sci. U.S.A. 86 787-791.

MicroRNA Expression in Patient Metastatic Brain Lesions
Principal Investigator

MicroRNA Expression in Patient Primary Brain Tumors
Principal Investigator

A pilot study to compare non-coding RNA in multiple myeloma patients, MGUS patients and healthy individuals using bone marrow and peripheral blood
Principal Investigator

A pilot study to compare the isolation of circulating tumor cells from peripheral blood and by diagnostic leukapheresis in multiple myeloma patients and healthy individuals
Principal Investigator

Specific targeting of bone marrow niche-resident long lived plasma cells by combined therapy with bortezomib and plerixafor
Co-Principal Investigator; Sponsor - Millennium-Takeda, Cambridge, MA

Velcade-based Desensitization Kidney Transplant Protocol Synopsis
Co-Principal Investigator; Sponsor- Onyx Pharmaceuticals – South San Francisco, CA

A phase I/II clinical trial of Metformin combined with Velcade and Dexamethasone in newly diagnosed Multiple Myeloma
Principal Investigator

A Phase 1 Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
Co-Investigator

Global Non-Coding RNA Studies from Peripheral Blood and Bone Marrow-derived CD138+ Cells in Multiple Myeloma, MGUS and Healthy Volunteers.